Tyrosine kinase inhibitors (TKI) induce prolonged remission in CML, and therapy discontinuation is an accepted approach to patients with reduction in Bcr–abl transcripts of four logs or greater. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.